Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project
NCT03799341 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63
Last updated 2025-09-30
Summary
The proposed work will investigate changes in brain signaling and cognitive functioning that support recovery from addiction, as well as use of pretreatment neurocognitive functioning to inform substance use treatment planning. Substance use disorders are prevalent amongst Veterans. Cocaine addiction, in particular, has been shown to complicate treatment of other high priority behavioral health problems in the Veteran population (e.g., PTSD, opioid addiction). While there are currently no approved medications to support recovery from cocaine addiction, research indicates that Contingency Management (CM) - a behavioral intervention for cocaine users - can be effective. However, individual responses are variable and long-term benefits are limited. This CDA will test a new model of how CM works by examining brain-based predictors and indicators of treatment response. Results will have immediate implications for measurement-based implementation of existing CM variants within the VA, supporting access to the version of CM that is best aligned with each Veteran's needs.
Conditions
- Cocaine Use Disorder
Interventions
- BEHAVIORAL
-
Prize-Based Contingency Management
Participants assigned to Prize-based Contingency Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8 prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment.
- BEHAVIORAL
-
Treatment As Usual Outpatient Substance Use Treatment
All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
Sponsors & Collaborators
-
VA Office of Research and Development
lead FED
Principal Investigators
-
Sarah E. Forster, PhD · VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-11-13
- Primary Completion
- 2023-10-31
- Completion
- 2024-04-12
Countries
- United States
Study Locations
More Related Trials
-
Temporal Window and Episodic Future Thinking in CUD
NCT05507814 ·Status: COMPLETED ·Phase: NA
-
Extending Long-term Outcomes Through an Adaptive Aftercare Intervention
NCT02143063 ·Status: COMPLETED ·Phase: NA
-
Impulsivity, Neural Deficits and Cocaine Addiction
NCT00744601 ·Status: COMPLETED
-
Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction
NCT01978457 ·Status: TERMINATED ·Phase: PHASE1
-
Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial
NCT00877435 ·Status: COMPLETED ·Phase: NA
-
Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse
NCT02080819 ·Status: COMPLETED ·Phase: PHASE2
-
Predicting Relapse After Cocaine Inpatient Cessation
NCT02416050 ·Status: COMPLETED
-
Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence
NCT00376558 ·Status: COMPLETED ·Phase: NA
-
Brain Changes in Stimulant Dependent Subjects - 8
NCT00000343 ·Status: COMPLETED ·Phase: PHASE4
-
Cognitive Enhancement and Relapse Prevention in Cocaine Addiction
NCT01067846 ·Status: COMPLETED ·Phase: NA
-
Pharmacotherapy & CM for Opioid and Cocaine Dependence
NCT00838981 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study
NCT00292136 ·Status: COMPLETED
-
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence
NCT01468012 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prize Contingency Management for Cocaine-Dependent Methadone Patients
NCT01401270 ·Status: COMPLETED ·Phase: NA
-
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use
NCT02444208 ·Status: COMPLETED ·Phase: NA
-
Alterations in Serotonergic Functions in Cocaine Addicts - 1
NCT00000312 ·Status: COMPLETED ·Phase: PHASE1
-
Behavioral Incentives to Increase Exercise in Cocaine Dependent Women
NCT01283191 ·Status: COMPLETED ·Phase: NA
-
Reward Processing in Cocaine Addiction
NCT01036074 ·Status: COMPLETED
-
Contingency Management for Persons With Severe Mental Illness
NCT01478815 ·Status: COMPLETED ·Phase: NA
-
M-CPP and Fenfluramine in Cocaine Addicts - 3
NCT00000314 ·Status: COMPLETED ·Phase: PHASE2
-
5HT2CR Balance in Brain Connectivity in Cocaine Dependence
NCT03921151 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1
NCT00094315 ·Status: UNKNOWN ·Phase: PHASE1
-
Neurofeedback During Naturalistic Stimuli to Reduce Craving in Heroin Addiction
NCT07344233 ·Status: COMPLETED ·Phase: NA
-
Assessing the Impact of Varenicline on Brain-Behavior Vulnerability
NCT00895557 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Effect of Glutamatergic Modulation on Cocaine Self-administration
NCT02596022 ·Status: COMPLETED ·Phase: PHASE2